在接受卡普拉西祖马布治疗的免疫媒介性血栓性血栓塞性紫外线患者中进行复杂的免疫性评估,这些患者已经接受了血交换
Brendy Van Butsel1, Maria Laura Sargentini-Maier1, Ana Paula Marques2
1Sanofi, Ghent, Belgium.
Research and practice in thrombosis and haemostasis
|December 17, 2024
概括
治疗性血交换 (TPE) 和免疫抑制疗法 (IST) 在接受卡普拉西祖马布治疗的免疫媒介性血栓性血栓性斑疹 (iTTP) 患者中复杂化抗药抗体 (ADA) 测量. 很少有患者患有治疗出现的ADA,没有人影响疗效或安全.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前针对免疫媒介性血栓性血栓性缺血性紫外线 (iTTP) 的指导方针建议同时进行治疗性血交换 (TPE),免疫抑制疗法 (IST) 和caplacizumab.
- 治疗性血交换 (TPE) 可以通过引入先前存在的抗体或稀释治疗出现的抗体来干扰抗药抗体 (ADA) 测量.
研究的目的:
- 评估接受caplacizumab的iTTP患者的抗药抗体 (ADA) 的存在和影响.
主要方法:
- 分析了来自四项临床试验的228名患者的免疫原性数据.
- 专门的测试区分了先前存在的抗体 (pre-Abs) 与治疗新出现的ADA (TE ADA).
- 功能中和抗体 (NAb) 和中和表位特征测试 (NECA) 评估了中和潜力,并评估了对疗效,药理动力学/药理动力学和安全性的影响.
主要成果:
- 在不同研究中,先前存在的抗体 (pre-Abs) 的患病率从17.1%到56.7%不等.
- 治疗出现的ADA (TE ADA) 患病率在3.1%至14.3%之间.
- ADAs的存在没有影响治疗疗效,药理动力学/药理动力学或安全性.
结论:
- 需要一个复杂的免疫性测定策略,以准确确定 iTTP 患者的 ADA 状态.
- 很少有患者发展出可检测的治疗产生的ADA或中和抗体,而这些并没有影响临床结果.
更多相关视频
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
15.7K
04:32A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
Published on: June 5, 2019
7.6K
相关概念视频
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
